Anika Inorganic Growth Offsets COVID Declines

Anika Therapeutics' logo

Anika Therapeutics reported 2Q20 orthopedic revenue of USD $28.9 million, +5.2% vs. 2Q19. The company exceeded aggressive internal expectations in the face of the COVID pandemic. Sports medicine procedure volumes increased through the quarter with April at 25% of historical volume, May at 50% and June at 80%. July’s volume trend was at...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us